vesnarinone has been researched along with Heart Failure in 65 studies
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Digoxin and other low doses of drugs that have inotropic properties may have an important role to play in the therapy of patients with chronic heart failure." | 10.17 | Reassessment of digoxin and other low-dose positive inotropes in the treatment of chronic heart failure. ( Gheorghiade, M; Han, D; Tauke, J, 1994) |
| "Treatment with 30 mg and 60 mg of vesnarinone had no effect on circulating levels of cytokines or cytokine receptors in patients with advanced heart failure over a 24-week period." | 9.09 | Effects of vesnarinone on peripheral circulating levels of cytokines and cytokine receptors in patients with heart failure: a report from the Vesnarinone Trial. ( Deswal, A; Feldman, AM; Mann, DL; Petersen, NJ; White, BG, 2001) |
| "Vesnarinone has yielded controversial results on morbidity in patients with congestive heart failure." | 9.08 | Effect of vesnarinone on cardiac function in patients with severe congestive heart failure. ( Cocca-Spofford, D; Dec, GW; DiSalvo, TG; Picard, MH; Scherrer-Crosbie, M; Semigran, MJ, 1998) |
| "Vesnarinone is associated with a dose-dependent increase in mortality among patients with severe heart failure, an increase that is probably related to an increase in deaths due to arrhythmia." | 9.08 | A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. ( Bourge, RC; Cohn, JN; DeMets, DL; Goldstein, SO; Gottlieb, SO; Greenberg, BH; Jaski, BE; Lorell, BH; McGrew, F; White, BG, 1998) |
| "Six months of therapy with 60 mg of vesnarinone per day resulted in lower morbidity and mortality and improved the quality of life of patients with congestive heart failure." | 9.07 | Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. ( Bain, RP; Bristow, MR; Carson, PE; Feldman, AM; Gilbert, EM; Hendrix, GH; Parmley, WW; Pepine, CJ; Powers, ER; Strobeck, JE, 1993) |
| "Carvedilol and vesnarinone are drugs attracting recent interest in the treatment of chronic heart failure." | 8.81 | Carvedilol and vesnarinone: new antiarrhythmic approach in heart failure therapy. ( Cheng, JH; Kamiya, K; Kodama, I, 2001) |
| "Vesnarinone, a quinolinone derivative, is a recently synthesized positive inotropic agent that has been shown to dramatically improve the survival of patients with heart failure." | 7.69 | Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. ( Matsui, S; Matsumori, A; Sasayama, S; Shioi, T; Yamada, T, 1994) |
| "Intravenous drip of sodium pentobarbital 6 mg/kg per min induced obvious heart failure of anesthetic dogs (n = 11) followed by an infusion of 0." | 7.68 | [Effect of Chinese-made vesnarinone on experimental heart failure of dog]. ( Du, J; Yang, Z, 1992) |
| "Vesnarinone is a novel oral agent that improves survival and symptoms of patients with dilated cardiomyopathy." | 6.68 | Dose dependence of chronic positive inotropic effect of vesnarinone in patients with congestive heart failure due to idiopathic or ischemic cardiomyopathy. ( Becker, LC; Feldman, AM; Kasper, EK; Kass, DA; Van Anden, E; White, WB, 1996) |
| "Digoxin and other low doses of drugs that have inotropic properties may have an important role to play in the therapy of patients with chronic heart failure." | 6.17 | Reassessment of digoxin and other low-dose positive inotropes in the treatment of chronic heart failure. ( Gheorghiade, M; Han, D; Tauke, J, 1994) |
| "Vesnarinone is a new and novel inotropic drug that has unique and complex mechanisms of action." | 5.29 | Vesnarinone: a new inotropic agent for treating congestive heart failure. ( Cavusoglu, E; Frishman, WH; Klapholz, M, 1995) |
| "Treatment with 30 mg and 60 mg of vesnarinone had no effect on circulating levels of cytokines or cytokine receptors in patients with advanced heart failure over a 24-week period." | 5.09 | Effects of vesnarinone on peripheral circulating levels of cytokines and cytokine receptors in patients with heart failure: a report from the Vesnarinone Trial. ( Deswal, A; Feldman, AM; Mann, DL; Petersen, NJ; White, BG, 2001) |
| "Vesnarinone has yielded controversial results on morbidity in patients with congestive heart failure." | 5.08 | Effect of vesnarinone on cardiac function in patients with severe congestive heart failure. ( Cocca-Spofford, D; Dec, GW; DiSalvo, TG; Picard, MH; Scherrer-Crosbie, M; Semigran, MJ, 1998) |
| "Vesnarinone is associated with a dose-dependent increase in mortality among patients with severe heart failure, an increase that is probably related to an increase in deaths due to arrhythmia." | 5.08 | A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. ( Bourge, RC; Cohn, JN; DeMets, DL; Goldstein, SO; Gottlieb, SO; Greenberg, BH; Jaski, BE; Lorell, BH; McGrew, F; White, BG, 1998) |
| "Six months of therapy with 60 mg of vesnarinone per day resulted in lower morbidity and mortality and improved the quality of life of patients with congestive heart failure." | 5.07 | Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. ( Bain, RP; Bristow, MR; Carson, PE; Feldman, AM; Gilbert, EM; Hendrix, GH; Parmley, WW; Pepine, CJ; Powers, ER; Strobeck, JE, 1993) |
| "Carvedilol and vesnarinone are drugs attracting recent interest in the treatment of chronic heart failure." | 4.81 | Carvedilol and vesnarinone: new antiarrhythmic approach in heart failure therapy. ( Cheng, JH; Kamiya, K; Kodama, I, 2001) |
| " The methods are illustrated with analysis of data from the Vesnarinone trial of patients with severe heart failure, in which quality of life was assessed with the Minnesota Living with Heart Failure Questionnaire." | 3.71 | Item response models for joint analysis of quality of life and survival. ( Anderson, S; Douglas, J; Wang, C, 2002) |
| "Vesnarinone, a quinoline derivative with modest positive inotropic action, has been shown in several studies to benefit patients with clinical congestive heart failure." | 3.70 | Differential response to vesnarinone by cardiac fibroblasts isolated from normal and aortic regurgitant hearts. ( Borer, JS; Goldfine, SM; Herrold, EM; Ross, JS, 1998) |
| "Vesnarinone, a quinolinone derivative, is a recently synthesized positive inotropic agent that has been shown to dramatically improve the survival of patients with heart failure." | 3.69 | Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. ( Matsui, S; Matsumori, A; Sasayama, S; Shioi, T; Yamada, T, 1994) |
| " An example is given using a subset of exercise data from a clinical trial of vesnarinone in congestive heart failure." | 3.69 | Nonparametric test of stochastic ordering for multiple longitudinal measures. ( Bain, RP; Lachin, JM; Rosenberger, WF, 1995) |
| "Intravenous drip of sodium pentobarbital 6 mg/kg per min induced obvious heart failure of anesthetic dogs (n = 11) followed by an infusion of 0." | 3.68 | [Effect of Chinese-made vesnarinone on experimental heart failure of dog]. ( Du, J; Yang, Z, 1992) |
| "The efficacy of orally active 3, 4-dihydro-6-[4-(3,4- dimethoxybenzoyl )-1-piperazinyl]-2(1H)- quin olinone ( OPC -8212) as a positive inotropic agent was examined using model right-sided heart failure dogs and compared with those of dobutamine and amrinone." | 3.67 | Positive inotropic effect of 3, 4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-qu inolinone (OPC-8212) in the dog with experimentally-induced right-sided heart failure. ( Hashimoto, K; Mori, T; Yabuuchi, Y; Yamashita, S, 1984) |
| "Vesnarinone Trial (VesT) was a three-armed, placebo-controlled, randomized clinical trial designed to study the effects of 30 mg or 60 mg/day vesnarinone." | 2.79 | Visualization and dynamics of multidimensional health-related quality-of-life-adjusted overall survival: a new analytic approach. ( Andrei, AC; Grady, KL, 2014) |
| "Vesnarinone is a novel oral agent that improves survival and symptoms of patients with dilated cardiomyopathy." | 2.68 | Dose dependence of chronic positive inotropic effect of vesnarinone in patients with congestive heart failure due to idiopathic or ischemic cardiomyopathy. ( Becker, LC; Feldman, AM; Kasper, EK; Kass, DA; Van Anden, E; White, WB, 1996) |
| " of the high dosage used in the Vesnarinone Study Group Trial (VSGT), and of both dosages used in the Vesnarinone Trial (VEST)] a dose-dependent increase in mortality was identified for vesnarinone 30-120 mg/day." | 2.42 | Clinical characteristics of vesnarinone. ( Feldman, AM, 2004) |
| " The long-term use of an inotropic agent in the energy-starved failing heart has been expected to increase myocardial energy use and accelerate the disease process." | 2.42 | Optimising outcomes in end-stage heart failure: differences in therapeutic responses between diverse ethnic groups. ( Sasayama, S, 2004) |
| "This article reviews the precautions and adverse effects associated with vesnarinone use, and the potential mechanisms responsible for these complications as well as suggested treatment strategies." | 2.42 | Precautions for use and adverse effects of vesnarinone: potential mechanisms and future therapies. ( Bertolet, BD, 2004) |
| "For example, a study of congestive heart failure may schedule patients to undergo exercise testing at 12 weeks, but this measurement may be missing for those who died of heart disease during the study." | 2.40 | Worst-rank score analysis with informatively missing observations in clinical trials. ( Lachin, JM, 1999) |
| "The crucial issues in the management of congestive heart failure (CHF) are improvement of depressed myocardial contractility and reduction of excessive load." | 2.38 | [New oral drugs for the treatment of congestive heart failure]. ( Hayashida, W; Kawai, C; Kumada, T, 1992) |
| "Vesnarinone is a new and novel inotropic drug that has unique and complex mechanisms of action." | 1.29 | Vesnarinone: a new inotropic agent for treating congestive heart failure. ( Cavusoglu, E; Frishman, WH; Klapholz, M, 1995) |
| "Eleven patients with moderate congestive heart failure received a single mean dose of 6." | 1.27 | Acute hemodynamic effects of a new inotropic agent (OPC-8212) in patients with congestive heart failure. ( Asanoi, H; Iuchi, K; Kameyama, T; Sasayama, S, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (15.38) | 18.7374 |
| 1990's | 39 (60.00) | 18.2507 |
| 2000's | 15 (23.08) | 29.6817 |
| 2010's | 1 (1.54) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Erhardt, PW | 1 |
| Andrei, AC | 1 |
| Grady, KL | 1 |
| Teerlink, JR | 1 |
| Metra, M | 1 |
| Zacà, V | 1 |
| Sabbah, HN | 1 |
| Cotter, G | 1 |
| Gheorghiade, M | 2 |
| Cas, LD | 1 |
| Sasayama, S | 16 |
| De Luca, L | 1 |
| Proietti, P | 1 |
| Palombaro, GL | 1 |
| Battagliese, A | 1 |
| Celotto, A | 1 |
| Bucciarelli Ducci, C | 1 |
| Fedele, F | 1 |
| Young, JB | 3 |
| Feldman, AM | 11 |
| Bertolet, BD | 1 |
| Eickhoff, JC | 1 |
| Hashimoto, K | 1 |
| Yabuuchi, Y | 1 |
| Yamashita, S | 1 |
| Mori, T | 1 |
| Lan, KK | 1 |
| Rosenberger, WF | 2 |
| Lachin, JM | 3 |
| Tauke, J | 1 |
| Han, D | 1 |
| Matsumori, A | 7 |
| Shioi, T | 2 |
| Yamada, T | 1 |
| Matsui, S | 1 |
| Strobeck, JE | 5 |
| Swedberg, K | 1 |
| Wedel, H | 1 |
| Neely, D | 1 |
| Schwartz, A | 1 |
| Grupp, I | 1 |
| Grupp, G | 1 |
| Bristow, MR | 1 |
| Parmley, WW | 1 |
| Carson, PE | 1 |
| Pepine, CJ | 1 |
| Gilbert, EM | 1 |
| Hendrix, GH | 1 |
| Powers, ER | 1 |
| Bain, RP | 2 |
| Packer, M | 1 |
| Sato, Y | 2 |
| Asanoi, H | 4 |
| Inoue, H | 1 |
| Kass, DA | 1 |
| Van Anden, E | 1 |
| Becker, LC | 3 |
| Kasper, EK | 1 |
| White, WB | 1 |
| Toyama, J | 1 |
| Kamiya, K | 2 |
| Cheng, J | 1 |
| Lee, JK | 1 |
| Suzuki, R | 1 |
| Kodama, I | 2 |
| Ono, K | 1 |
| Nose, Y | 1 |
| Vander Heide, RS | 1 |
| Marsh, JD | 1 |
| Cavusoglu, E | 1 |
| Frishman, WH | 1 |
| Klapholz, M | 1 |
| Scherrer-Crosbie, M | 1 |
| Cocca-Spofford, D | 1 |
| DiSalvo, TG | 1 |
| Semigran, MJ | 1 |
| Dec, GW | 1 |
| Picard, MH | 1 |
| Cohn, JN | 3 |
| Goldstein, SO | 1 |
| Greenberg, BH | 1 |
| Lorell, BH | 1 |
| Bourge, RC | 1 |
| Jaski, BE | 1 |
| Gottlieb, SO | 1 |
| McGrew, F | 1 |
| DeMets, DL | 1 |
| White, BG | 5 |
| Stevenson, LW | 1 |
| Ross, JS | 1 |
| Goldfine, SM | 1 |
| Herrold, EM | 1 |
| Borer, JS | 1 |
| Pitt, B | 1 |
| Nicklas, JM | 1 |
| Pritzker, MR | 1 |
| Alhaddad, IA | 1 |
| Soran, O | 1 |
| Young, JD | 1 |
| Holubkov, R | 2 |
| Loftus, S | 1 |
| Bourge, R | 1 |
| Carson, P | 1 |
| Jaski, B | 1 |
| Reis, SE | 1 |
| LeJemtel, TH | 1 |
| Deswal, A | 2 |
| Petersen, NJ | 2 |
| Mann, DL | 2 |
| van Veldhuisen, DJ | 1 |
| Poole-Wilson, PA | 1 |
| Cheng, JH | 1 |
| Wang, C | 1 |
| Douglas, J | 1 |
| Anderson, S | 1 |
| Hayashida, W | 1 |
| Kumada, T | 1 |
| Kawai, C | 2 |
| Du, J | 1 |
| Yang, Z | 1 |
| Baughman, KL | 3 |
| Lee, WK | 1 |
| Gottlieb, SH | 1 |
| Weiss, JL | 1 |
| Kameyama, T | 2 |
| Ishizaka, S | 1 |
| Iuchi, K | 2 |
| Llewellyn, MP | 1 |
| Inoue, M | 3 |
| Hori, M | 3 |
| Yasuda, H | 1 |
| Takishima, T | 1 |
| Sugimoto, T | 1 |
| Sakurai, T | 2 |
| Nonogi, H | 1 |
| Kodama, K | 3 |
| Kusukawa, R | 1 |
| Kubo, SH | 1 |
| Rector, TS | 1 |
| Fukuda, K | 1 |
| Handa, S | 1 |
| Ogawa, S | 1 |
| Nakamura, Y | 1 |
| Kawamura, Y | 1 |
| Kim, BH | 1 |
| Tsuneoka, Y | 1 |
| Matsubara, N | 1 |
| Kamada, T | 1 |
| Naka, M | 1 |
| Nanto, S | 1 |
| Higashino, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Monocyte Phenotypic Changes in Heart Failure[NCT02997462] | 60 participants (Anticipated) | Observational | 2011-11-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
20 reviews available for vesnarinone and Heart Failure
| Article | Year |
|---|---|
In search of the digitalis replacement.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Cardiotonic Agents; Cyclic AMP; Digitalis Glycosides; Heart Fai | 1987 |
Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond.
Topics: Acute Disease; Cardiotonic Agents; Digoxin; Dobutamine; Etiocholanolone; Exercise Test; Heart Failur | 2009 |
[Inotropic agents].
Topics: Adrenergic alpha-Agonists; Animals; Cardiotonic Agents; Clinical Trials as Topic; Digitalis Glycosid | 2003 |
New positive inotropic agents in the treatment of left ventricular dysfunction.
Topics: Cardiotonic Agents; Diastole; Heart Failure; Humans; Hydrazones; Milrinone; Myocardial Ischemia; Pho | 2004 |
Clinical characteristics of vesnarinone.
Topics: Algorithms; Controlled Clinical Trials as Topic; Heart Failure; Humans; Multicenter Studies as Topic | 2004 |
Optimising outcomes in end-stage heart failure: differences in therapeutic responses between diverse ethnic groups.
Topics: Asian People; Clinical Trials as Topic; Heart Failure; Humans; Pyrazines; Quinolines; Treatment Outc | 2004 |
Precautions for use and adverse effects of vesnarinone: potential mechanisms and future therapies.
Topics: Animals; Clinical Trials as Topic; Death, Sudden; Heart Failure; Humans; Monitoring, Physiologic; Mu | 2004 |
Reassessment of digoxin and other low-dose positive inotropes in the treatment of chronic heart failure.
Topics: Adrenergic beta-Agonists; Cardiotonic Agents; Digoxin; Double-Blind Method; Drug Evaluation; Electro | 1994 |
Quinolinone derivatives in the management of congestive heart failure.
Topics: Animals; Cardiotonic Agents; Heart Failure; Humans; Pyrazines; Quinolines; Quinolones | 1994 |
[Role of cytokines in etiological mechanism of congestive heart failure].
Topics: Cardiotonic Agents; Cytokines; Cytotoxicity, Immunologic; Heart Failure; Humans; Killer Cells, Natur | 1995 |
Immunomodulating agents for the management of heart failure with myocarditis and cardiomyopathy--lessons from animal experiments.
Topics: Adjuvants, Immunologic; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; B | 1995 |
Vesnarinone: a potential cytokine inhibitor.
Topics: Adjuvants, Immunologic; Animals; Cytokines; Heart Failure; Humans; Pyrazines; Quinolines | 1996 |
Ion channel blockers in the treatment of chronic heart failure.
Topics: Amiodarone; Animals; Calcium Channel Blockers; Chronic Disease; Heart Failure; Humans; Potassium Cha | 1996 |
Inotropic agents in the treatment of heart failure: despair or hope?
Topics: Adrenergic beta-Agonists; Cardiotonic Agents; Cyclic AMP; Digitalis; Heart Failure; Humans; Plants, | 1997 |
Heart failure: clinical implications of recent trials.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Diuretics; Heart Failure; Humans; Pyra | 1994 |
Worst-rank score analysis with informatively missing observations in clinical trials.
Topics: Cardiotonic Agents; Data Interpretation, Statistical; Follow-Up Studies; Heart Failure; Humans; Pyra | 1999 |
Review of a dose-dependent increase in mortality with vesnarinone among patients with severe heart failure.
Topics: Cardiotonic Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Heart Failure; Human | 1999 |
The underreporting of results and possible mechanisms of 'negative' drug trials in patients with chronic heart failure.
Topics: Bosentan; Cardiovascular Agents; Deoxyepinephrine; Heart Failure; Humans; Imidazoles; Mibefradil; Py | 2001 |
Carvedilol and vesnarinone: new antiarrhythmic approach in heart failure therapy.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Calcium Channels, L-Type; Carbazoles; Cardiotoni | 2001 |
[New oral drugs for the treatment of congestive heart failure].
Topics: Administration, Oral; Cardiotonic Agents; Deoxyepinephrine; Ethanolamines; Heart Failure; Humans; Ph | 1992 |
14 trials available for vesnarinone and Heart Failure
| Article | Year |
|---|---|
Visualization and dynamics of multidimensional health-related quality-of-life-adjusted overall survival: a new analytic approach.
Topics: Cardiotonic Agents; Cohort Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; F | 2014 |
Reassessment of digoxin and other low-dose positive inotropes in the treatment of chronic heart failure.
Topics: Adrenergic beta-Agonists; Cardiotonic Agents; Digoxin; Double-Blind Method; Drug Evaluation; Electro | 1994 |
Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group.
Topics: Adult; Aged; Aged, 80 and over; Cardiotonic Agents; Double-Blind Method; Female; Follow-Up Studies; | 1993 |
Dose dependence of chronic positive inotropic effect of vesnarinone in patients with congestive heart failure due to idiopathic or ischemic cardiomyopathy.
Topics: Administration, Oral; Cardiomyopathies; Cardiotonic Agents; Dose-Response Relationship, Drug; Double | 1996 |
Effect of vesnarinone on cardiac function in patients with severe congestive heart failure.
Topics: Aged; Cardiotonic Agents; Echocardiography; Female; Heart Failure; Hemodynamics; Humans; Male; Middl | 1998 |
A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators.
Topics: Aged; Agranulocytosis; Angiotensin-Converting Enzyme Inhibitors; Arrhythmias, Cardiac; Cardiotonic A | 1998 |
Effect of inotrope withdrawal on morbidity and mortality in patients with chronic heart failure: results of the vesnarinone trial withdrawal substudy. Vest Withdrawal Substudy Group.
Topics: Cardiotonic Agents; Cause of Death; Chronic Disease; Disease Progression; Follow-Up Studies; Heart F | 1999 |
Effects of vesnarinone on peripheral circulating levels of cytokines and cytokine receptors in patients with heart failure: a report from the Vesnarinone Trial.
Topics: Cardiotonic Agents; Cytokines; Enzyme-Linked Immunosorbent Assay; Female; Heart Failure; Humans; Int | 2001 |
Oral milrinone in severe chronic heart failure.
Topics: Cardiotonic Agents; Heart Failure; Humans; Milrinone; Pyrazines; Pyridones; Quinolines | 1992 |
Usefulness of OPC-8212, a quinolinone derivative, for chronic congestive heart failure in patients with ischemic heart disease or idiopathic dilated cardiomyopathy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Cardiomyopathy, Dilated; Cardioton | 1991 |
A placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failure. OPC-8212 Multicenter Research Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Pressure; Cardiotonic Agents; Chronic Disease; Dou | 1990 |
Sustained inotropic effects of a new cardiotonic agent. OPC-8212 in patients with chronic heart failure.
Topics: Adult; Aged; Cardiotonic Agents; Clinical Trials as Topic; Female; Heart Failure; Humans; Male; Midd | 1989 |
Evaluation of a new inotropic agent, OPC-8212, in patients with dilated cardiomyopathy and heart failure.
Topics: Adult; Cardiomyopathy, Dilated; Cardiotonic Agents; Clinical Trials as Topic; Exercise Test; Female; | 1988 |
A multicenter study of a new inotropic agent, piperanometozine (OPC-8212) in congestive heart failure: clinical improvement during short-term treatment.
Topics: Aged; Cardiotonic Agents; Female; Heart Failure; Humans; Male; Middle Aged; Pyrazines; Quinolines | 1987 |
32 other studies available for vesnarinone and Heart Failure
| Article | Year |
|---|---|
Inotropic agents and immune modulation.
Topics: Adjuvants, Immunologic; Animals; Cardiotonic Agents; Clinical Trials as Topic; Cytokines; Heart Fail | 2002 |
The best of times, the worst of times: the wealth and poverty of heart failure pharmacotherapies: is there a role for vesnarinone?
Topics: Clinical Trials as Topic; Drug Therapy; Forecasting; Heart Failure; Humans; Pyrazines; Quinolines; Q | 2004 |
Placebo effect-adjusted assessment of quality of life in placebo-controlled clinical trials.
Topics: Algorithms; Biometry; Cardiotonic Agents; Clinical Trials, Phase III as Topic; Controlled Clinical T | 2008 |
Positive inotropic effect of 3, 4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-qu inolinone (OPC-8212) in the dog with experimentally-induced right-sided heart failure.
Topics: Administration, Oral; Aminopyridines; Amrinone; Animals; Blood Pressure; Cardiotonic Agents; Dobutam | 1984 |
Sequential monitoring of survival data with the Wilcoxon statistic.
Topics: Biometry; Cardiotonic Agents; Clinical Trials as Topic; Follow-Up Studies; Heart Failure; Humans; Li | 1995 |
Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure.
Topics: Blood; Cardiotonic Agents; Cytokines; Enzyme-Linked Immunosorbent Assay; Female; Heart Failure; Huma | 1994 |
Vesnarinone for heart failure.
Topics: Cardiotonic Agents; Heart Failure; Humans; Pyrazines; Quinolines | 1994 |
Vesnarinone for heart failure.
Topics: Cardiotonic Agents; Heart Failure; Humans; Pyrazines; Quinolines | 1994 |
Vesnarinone for heart failure.
Topics: Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Myocardial Contraction; Pyrazines; Quinolin | 1994 |
The search for the ideal positive inotropic agent.
Topics: Cardiotonic Agents; Heart Failure; Humans; Myocardial Contraction; Pyrazines; Quinolines | 1993 |
Inotropic agent vesnarinone inhibits cytokine production and E-selectin expression in human umbilical vein endothelial cells.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Amrinone; Cardiotonic Agents; Cell Adhesion; Cells, Cultured | 1995 |
Nonparametric test of stochastic ordering for multiple longitudinal measures.
Topics: Cardiotonic Agents; Double-Blind Method; Heart Failure; Humans; Longitudinal Studies; Multicenter St | 1995 |
Role of cytokines in the syndrome of heart failure.
Topics: Adrenergic beta-Agonists; Amrinone; Animals; Cardiotonic Agents; Cytokines; Heart Failure; Humans; K | 1996 |
Positive inotropic agents: a double-edged sword for chronic heart failure.
Topics: Cardiotonic Agents; Chronic Disease; Clinical Trials as Topic; Dose-Response Relationship, Drug; Hea | 1996 |
Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; 4-(3-Butoxy-4-methoxybenzy | 1996 |
Through the looking glass: a positive inotropic drug and ischemic preconditioning.
Topics: 5'-Nucleotidase; Adenosine; Animals; Cardiotonic Agents; Dogs; Drug Approval; Enzyme Activation; Hea | 1997 |
[Drug therapy of congestive heart failure].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Car | 1997 |
Vesnarinone: a new inotropic agent for treating congestive heart failure.
Topics: Cardiotonic Agents; Clinical Trials as Topic; Cytokines; Heart Failure; Hemodynamics; Humans; Pyrazi | 1995 |
Inotropic therapy for heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Death, Sudden; Disease Progression; Di | 1998 |
Differential response to vesnarinone by cardiac fibroblasts isolated from normal and aortic regurgitant hearts.
Topics: Animals; Aortic Valve Insufficiency; Cardiotonic Agents; Cell Survival; Cells, Cultured; Dose-Respon | 1998 |
Severe heart failure: balancing length and quality of life.
Topics: Amrinone; Cardiotonic Agents; Heart Failure; Humans; Milrinone; Phosphodiesterase Inhibitors; Pyrazi | 1999 |
Chronic heart failure and the quality of life.
Topics: Cardiotonic Agents; Heart Failure; Humans; Milrinone; Palliative Care; Pyrazines; Quality of Life; Q | 1999 |
Chronic heart failure and the quality of life.
Topics: Cardiotonic Agents; Heart Failure; Humans; Pyrazines; Quality of Life; Quinolines | 1999 |
Estrogen is associated with improved survival in aging women with congestive heart failure: analysis of the vesnarinone studies.
Topics: Aged; Cardiotonic Agents; Estradiol Congeners; Estrogen Replacement Therapy; Female; Heart Failure; | 2000 |
Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST).
Topics: Adult; Age Distribution; Age Factors; Aged; Aged, 80 and over; Antigens, CD; Biomarkers; Cardiotonic | 2001 |
Item response models for joint analysis of quality of life and survival.
Topics: Area Under Curve; Cardiotonic Agents; Clinical Trials as Topic; Computer Simulation; Heart Failure; | 2002 |
[Effect of Chinese-made vesnarinone on experimental heart failure of dog].
Topics: Animals; Cardiac Output; Cardiotonic Agents; Dogs; Female; Heart Failure; Hemodynamics; Male; Myocar | 1992 |
OPC-8212 in the treatment of congestive heart failure: results of a pilot study.
Topics: Aged; Cardiotonic Agents; Exercise Test; Female; Heart Failure; Hemodynamics; Humans; Male; Middle A | 1988 |
[Usefulness of OPC-8212, an inotropic agent, in patients with chronic congestive heart failure--a multiple dose evaluation on its effect and arrhythmogenesis].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Cardiotonic Agents; Drug | 1988 |
Acute hemodynamic effects of a new inotropic agent (OPC-8212) in patients with congestive heart failure.
Topics: Adult; Aged; Cardiac Output; Cardiotonic Agents; Drug Evaluation; Female; Heart Failure; Hemodynamic | 1987 |
Acute hemodynamic effects of a new inotropic agent, OPC-8212, on severe congestive heart failure.
Topics: Administration, Oral; Adult; Aged; Cardiac Output; Cardiomyopathy, Dilated; Cardiotonic Agents; Coro | 1986 |
Oral OPC-8212 for the treatment of congestive heart failure: hemodynamic improvement and increased exercise capacity.
Topics: Administration, Oral; Aged; Blood Pressure; Cardiotonic Agents; Female; Heart Failure; Heart Rate; H | 1986 |